JP2018533582A5 - - Google Patents

Download PDF

Info

Publication number
JP2018533582A5
JP2018533582A5 JP2018522126A JP2018522126A JP2018533582A5 JP 2018533582 A5 JP2018533582 A5 JP 2018533582A5 JP 2018522126 A JP2018522126 A JP 2018522126A JP 2018522126 A JP2018522126 A JP 2018522126A JP 2018533582 A5 JP2018533582 A5 JP 2018533582A5
Authority
JP
Japan
Prior art keywords
cancer
use according
pharmaceutically acceptable
acceptable salt
acid ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018522126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533582A (ja
JP6833844B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/059342 external-priority patent/WO2017075363A1/en
Publication of JP2018533582A publication Critical patent/JP2018533582A/ja
Publication of JP2018533582A5 publication Critical patent/JP2018533582A5/ja
Application granted granted Critical
Publication of JP6833844B2 publication Critical patent/JP6833844B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018522126A 2015-10-30 2016-10-28 アルギナーゼ活性を阻害する組成物及び方法 Active JP6833844B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562248632P 2015-10-30 2015-10-30
US62/248,632 2015-10-30
US201662281964P 2016-01-22 2016-01-22
US62/281,964 2016-01-22
US201662323034P 2016-04-15 2016-04-15
US62/323,034 2016-04-15
PCT/US2016/059342 WO2017075363A1 (en) 2015-10-30 2016-10-28 Compositions and methods for inhibiting arginase activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021014795A Division JP7032583B2 (ja) 2015-10-30 2021-02-02 アルギナーゼ活性を阻害する組成物及び方法

Publications (3)

Publication Number Publication Date
JP2018533582A JP2018533582A (ja) 2018-11-15
JP2018533582A5 true JP2018533582A5 (OSRAM) 2020-03-19
JP6833844B2 JP6833844B2 (ja) 2021-02-24

Family

ID=58631120

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018522126A Active JP6833844B2 (ja) 2015-10-30 2016-10-28 アルギナーゼ活性を阻害する組成物及び方法
JP2021014795A Expired - Fee Related JP7032583B2 (ja) 2015-10-30 2021-02-02 アルギナーゼ活性を阻害する組成物及び方法
JP2022025334A Withdrawn JP2022071010A (ja) 2015-10-30 2022-02-22 アルギナーゼ活性を阻害する組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021014795A Expired - Fee Related JP7032583B2 (ja) 2015-10-30 2021-02-02 アルギナーゼ活性を阻害する組成物及び方法
JP2022025334A Withdrawn JP2022071010A (ja) 2015-10-30 2022-02-22 アルギナーゼ活性を阻害する組成物及び方法

Country Status (36)

Country Link
US (4) US10065974B2 (OSRAM)
EP (3) EP4011887B1 (OSRAM)
JP (3) JP6833844B2 (OSRAM)
KR (2) KR20220118559A (OSRAM)
CN (4) CN108271371B (OSRAM)
AU (3) AU2016343656B2 (OSRAM)
BR (3) BR112018008746B1 (OSRAM)
CA (1) CA3003271A1 (OSRAM)
CL (4) CL2018001134A1 (OSRAM)
CO (1) CO2018004750A2 (OSRAM)
CR (3) CR20210390A (OSRAM)
CY (1) CY1123557T1 (OSRAM)
DK (2) DK4011887T3 (OSRAM)
EA (1) EA038276B1 (OSRAM)
EC (1) ECSP18040250A (OSRAM)
ES (3) ES2808988T3 (OSRAM)
HR (1) HRP20201046T1 (OSRAM)
HU (1) HUE054972T2 (OSRAM)
IL (3) IL258731B (OSRAM)
LT (1) LT3368541T (OSRAM)
MA (2) MA50636A (OSRAM)
MD (1) MD3368541T2 (OSRAM)
MX (1) MX2018005294A (OSRAM)
MY (1) MY201783A (OSRAM)
NZ (1) NZ742742A (OSRAM)
PH (2) PH12018500899B1 (OSRAM)
PL (1) PL3368541T3 (OSRAM)
PT (1) PT3368541T (OSRAM)
RS (1) RS60695B1 (OSRAM)
SG (4) SG10201911402YA (OSRAM)
SI (1) SI3368541T1 (OSRAM)
SM (1) SMT202000469T1 (OSRAM)
TW (3) TWI710565B (OSRAM)
UA (1) UA125289C2 (OSRAM)
WO (1) WO2017075363A1 (OSRAM)
ZA (4) ZA201803556B (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103068830B (zh) 2010-04-22 2016-06-29 马尔斯公司 精氨酸酶抑制剂及其治疗应用
ES2794006T3 (es) 2010-10-26 2020-11-17 Mars Inc Inhibidores de arginasa como agentes terapéuticos
PL3368541T3 (pl) 2015-10-30 2020-11-02 Calithera Biosciences, Inc. Kompozycje i sposoby hamowania aktywności arginazy
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX2019005402A (es) 2016-11-08 2019-12-05 Calithera Biosciences Inc Terapias de combinacion del inhibidor de arginasa.
PL3559009T3 (pl) 2016-12-22 2021-10-25 Calithera Biosciences, Inc. Kompozycje i sposoby hamowania aktywności arginazy
CR20190562A (es) * 2017-05-12 2020-03-04 Calithera Biosciences Inc Método para preparar (3r, 4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida
WO2019120296A1 (en) * 2017-12-22 2019-06-27 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
CN111712302B (zh) 2018-02-17 2023-09-19 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
CA3091805A1 (en) 2018-03-05 2019-09-12 Arcus Biosciences, Inc. Arginase inhibitors
US12215116B2 (en) 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
CA3094939A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
EP3810615A4 (en) 2018-06-20 2022-03-30 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
CA3120196A1 (en) 2018-11-16 2020-05-22 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
EP3897622A4 (en) 2018-12-18 2022-09-28 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
WO2020160707A1 (en) * 2019-02-06 2020-08-13 Guangdong Newopp Biopharmaceuticals Co., Ltd. Alkylboronic acids as arginase inhibitors
KR20220004726A (ko) * 2019-05-02 2022-01-11 어클라리스 쎄라퓨틱스, 인코포레이티드 Jak 억제제로서의 치환된 피롤로피리딘
MX2022000904A (es) * 2019-07-23 2022-05-02 Astrazeneca Ab Inhibidores de arginasa y métodos de uso de estos.
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
JP2023502182A (ja) 2019-11-12 2023-01-20 ナミ セラピューティクス， インコーポレイテッド がんの処置において有用なｉｄｏアンタゴニストプロドラッグを含有する製剤化および／または共製剤化されたリポソーム組成物およびその方法
WO2021141751A1 (en) * 2020-01-07 2021-07-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
HRP20250814T1 (hr) 2020-07-02 2025-09-12 Incyte Corporation Spojevi tricikličke uree kao jak2 v617f inhibitori
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US20220041630A1 (en) * 2020-07-17 2022-02-10 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
CA3211748A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
IL315647A (en) 2022-03-17 2024-11-01 Incyte Corp Tricyclic urea compounds as Jak2 and 617f inhibitors
WO2024086273A1 (en) 2022-10-21 2024-04-25 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US20240317744A1 (en) 2023-03-13 2024-09-26 Incyte Corporation Bicyclic Ureas As Kinase Inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
DK1348427T3 (da) 1997-07-29 2008-06-30 Alcon Lab Inc Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater
EP1049660A1 (en) 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
JP2004502948A (ja) 2000-07-06 2004-01-29 ファル　ダイアグノスティクス アルギニン化合物の検出のための方法及びキット
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
ES2593113T3 (es) 2003-08-07 2016-12-05 Allergan, Inc. Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2007005620A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Arginase ii: a target treatment of aging heart and heart failure
CN101755130B (zh) 2007-07-12 2012-10-17 山洋电气株式会社 双重反转式轴流鼓风机
US20090118243A1 (en) * 2007-10-12 2009-05-07 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of ophthalmic conditions
US20110129456A1 (en) * 2008-05-05 2011-06-02 Yaolin Wang Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
PL2389352T3 (pl) 2009-01-26 2019-10-31 Univ Pennsylvania Inhibitory arginazy oraz sposoby zastosowania
CN103068830B (zh) * 2010-04-22 2016-06-29 马尔斯公司 精氨酸酶抑制剂及其治疗应用
ES2794006T3 (es) 2010-10-26 2020-11-17 Mars Inc Inhibidores de arginasa como agentes terapéuticos
US8894970B2 (en) 2010-12-31 2014-11-25 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
AU2012326109A1 (en) 2011-10-19 2014-05-29 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
CN104394869A (zh) 2011-10-20 2015-03-04 葛兰素史密斯克莱有限责任公司 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物
US9200011B2 (en) 2012-04-18 2015-12-01 Mars, Incorporated Ring constrained analogs as arginase inhibitors
CA2890111A1 (en) * 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
TWI660739B (zh) * 2013-10-25 2019-06-01 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
CN105879030A (zh) * 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
CN107405404A (zh) 2015-03-20 2017-11-28 塞米·欧尤·奥皮约 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途
KR20180021117A (ko) 2015-06-23 2018-02-28 칼리테라 바이오사이언시즈, 인코포레이티드 아르기나제 활성 억제를 위한 조성물 및 방법
PL3368541T3 (pl) 2015-10-30 2020-11-02 Calithera Biosciences, Inc. Kompozycje i sposoby hamowania aktywności arginazy
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Similar Documents

Publication Publication Date Title
JP2018533582A5 (OSRAM)
IL292677A (en) Compositions and methods for inhibiting arginase activity
HRP20201046T1 (hr) Sastavi i metode za inhibitivnu aktivnost arginase
JP2020514271A5 (OSRAM)
US11912786B2 (en) Inhibitor of apoptosis protein (IAP) antagonists
US10604526B2 (en) Chemokine receptor modulators and uses thereof
ES2821790T3 (es) Moduladores de la vía de estrés integrada
EP2408300B1 (en) Amino ester derivatives, salts thereof and methods of use
JP2010533206A5 (OSRAM)
JP2019519599A (ja) 統合ストレス経路のモジュレーター
TW201945356A (zh) 趨化介素受體調節劑及其用途
KR20190031203A (ko) 통합 스트레스 경로의 조정제
WO2018049271A1 (en) Chemokine receptor modulators and uses thereof
EP3802544A1 (en) Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
ES2941790T3 (es) Copolímeros dibloque autoensamblados compuestos de PEGMEMA y segmentos poliméricos portadores de fármacos
JP2006507308A5 (OSRAM)
US20220274964A1 (en) 5-bromo-indirubins
JP2019194194A (ja) 癌を治療するためのｈｄａｃ８阻害剤
KR20070010125A (ko) 인테그린과 선택적으로 결합하는 피페리디닐 표적화 화합물
JP2019524852A5 (OSRAM)
US20140056849A1 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
JP2025525869A (ja) フェロトーシスを誘導するための組成物および方法
JP2023501038A (ja) 新規の治療的使用
JP2019536783A5 (OSRAM)
JP2014505052A (ja) 癌の治療および予防用の新規なウレア